Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
Epistemonikos ID: bfd6c03734b75d863e77f2db5b632cb67359ef0b
First added on: May 20, 2024